Navigation Links
Sequenom Announces Multi-Year Supply Agreement With Illumina
Date:7/11/2011

SAN DIEGO, July 11, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it has signed a three-year supply agreement with Illumina, Inc., a leading developer and manufacturer of life sciences tools for the large-scale analysis of genetic variation and function.

Under the terms of the agreement, Sequenom and its subsidiaries will purchase Illumina's sequencing equipment and consumables for use in the development of a noninvasive test designed to detect an overabundance of chromosome 21 in pregnant women, a result associated with fetal Down syndrome.  

Sequenom and Illumina will work collaboratively toward the submission for regulatory approval of an in vitro diagnostic product for the detection of fetal chromosomal abnormalities.

"We are pleased to announce this new partnership with Illumina, a leader in genetic sequencing systems, as we advance our role in developing and commercializing prenatal diagnostics," said Harry F. Hixson, Jr., Chairman and CEO of Sequenom, Inc. "This agreement is an important step in bringing our proprietary trisomy test to market, giving us the scalability, speed to market and supply chain necessary to address the commercial opportunity of our noninvasive prenatal test for trisomy 21."

"We are very pleased to complete this supply agreement with Sequenom for Illumina's HiSeq 2000 platform," said Jay Flatley, President and CEO of Illumina. "With the most powerful and cost-effective sequencing technology available, we are fully ready to meet Sequenom's needs as it prepares for the commercial launch of its test."

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

About Illumina

Illumina (NASDAQ: ILMN) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. Illumina also provides tools and services that are fueling advances in consumer genomics and diagnostics. Illumina's technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the duration of and performance expectations under the supply agreement, including purchases by Sequenom and collaborative efforts by Sequenom and Illumina toward a submission for regulatory approval of an in vitro diagnostic product, advancement of Sequenom's role in developing and commercializing prenatal diagnostics, bringing Sequenom's proprietary trisomy test to market, the expected impact of the supply agreement on Sequenom's scalability, speed to market, and supply chain, the commercial opportunity of Sequenom's noninvasive prenatal trisomy 21 test and its expected commercial launch, and Sequenom's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with reliance upon the collaborative efforts of other parties such as Illumina, Sequenom's ability to develop and commercialize new technologies and products, particularly new technologies such as prenatal and other diagnostics and laboratory developed tests, Sequenom's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation and investigations and other risks detailed from time to time in Sequenom, Inc.'s most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom, Inc. undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo:  http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Technology Collaboration Between New England Biolabs and Sequenom Delivers First Product for Epigenetics
2. Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results
3. Sequenom Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
4. Sequenom CMM Commences Pivotal Clinical Validation Study for Its SensiGene Trisomy 21 Laboratory Developed Test
5. Sequenom to Present at Two Financial Conferences in November
6. Sequenom Announces Date of Second Quarter 2010 Financial Results and Conference Call
7. Sequenom to Present at the Jefferies 2010 Global Life Sciences Conference
8. Sequenom Announces Final Approval of Settlement in Class Action Securities Lawsuit
9. Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results
10. Sequenom Announces Launch of SensiGene Fetal(XY) (Fetal Sex Determination) Test
11. Sequenom Announces Addition to Clinical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):